Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinomaJames B Brugarolas; Payal Kapur; Yair Lotan; Vitaly Margulis; Xian-Jin Xie)
Journal of Urology. 2014;191(3):603-610.Abstract
Purpose Mutations in the tumor suppressor gene BAP1 occur in approximately 15% of clear cell renal cell carcinoma cases. Sequencing efforts demonstrated worse outcomes in patients with BAP1 mutated clear cell renal cell carcinoma. We investigated the clinicopathological significance and oncologic outcomes of BAP1 loss using a previously validated immunohistochemical assay. Materials and Methods Immunohistochemistry for BAP1 was performed on tissue microarray sections from 559 nonmetastatic clear cell renal cell carcinoma cases treated with nephrectomy at multiple institutions. The association of BAP1 expression with clinicopathological parameters was analyzed using the Wilcoxon rank sum and Cochran-Mantel-Haenszel tests. Survival was assessed by Cox regression analysis, which also identified independent predictors of time dependent outcomes. Results At a median followup of 50 months (range 0 to 183) 86 of 483 patients (17.8%) experienced recurrence and 121 of 559 (21.6%) had died. BAP1 was negative in 82 of 559 tumors (14.7%). BAP1 loss was associated with adverse clinicopathological variables, including high Fuhrman grade (p <0.0001), advanced pT stage (p = 0.0021), sarcomatoid dedifferentiation (p = 0.0001) and necrosis (p <0.0001). Cox regression revealed that patients with BAP1 negative tumors had significantly worse disease-free survival (HR 2.9, 95% CI 1.8-4.7, p <0.0001) and overall survival (HR 2.0, 95% CI 1.3-3.1, p = 0.0010) than patients with BAP1 positive tumors. Conclusions Immunohistochemistry for BAP1 serves as a powerful marker to predict poor oncologic outcomes and adverse clinicopathological features in patients with nonmetastatic clear cell renal cell carcinoma. BAP1 assessment using immunohistochemistry on needle biopsy may benefit preoperative risk stratification and guide treatment planning in the future. © 2014 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Vitaly Margulis; Michelle McDonald; Pheroze Tamboli; David A. Swanson; Christopher G. WoodJournal of Urology. 2009;181(5):2044-2051.
Andrew B. Rosenkrantz; Aarti Sekhar; Elizabeth M. Genega; Jonathan Melamed; James S. Babb; Amish D. Patel; Andy Lo; Robert M. Najarian; Muneeb Ahmed; Ivan PedrosaEuropean Radiology. 2013;23(2):579-587.
Ephrem O. Olweny; Samuel K. Park; Yung K. Tan; Sara L. Best; Clayton Trimmer; Jeffrey A. CadedduEuropean Urology. 2012;61(6):1156-1161.
Appears in this Document